These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26312887)

  • 41. NMDA receptor activation enhances inhibitory GABAergic transmission onto hippocampal pyramidal neurons via presynaptic and postsynaptic mechanisms.
    Xue JG; Masuoka T; Gong XD; Chen KS; Yanagawa Y; Law SK; Konishi S
    J Neurophysiol; 2011 Jun; 105(6):2897-906. PubMed ID: 21471392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rett-like Severe Encephalopathy Caused by a De Novo GRIN2B Mutation Is Attenuated by D-serine Dietary Supplement.
    Soto D; Olivella M; Grau C; Armstrong J; Alcon C; Gasull X; Gómez de Salazar M; Gratacòs-Batlle E; Ramos-Vicente D; Fernández-Dueñas V; Ciruela F; Bayés À; Sindreu C; López-Sala A; García-Cazorla À; Altafaj X
    Biol Psychiatry; 2018 Jan; 83(2):160-172. PubMed ID: 28734458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Temperature dependence of N-methyl-D-aspartate receptor channels and N-methyl-D-aspartate receptor excitatory postsynaptic currents.
    Korinek M; Sedlacek M; Cais O; Dittert I; Vyklicky L
    Neuroscience; 2010 Feb; 165(3):736-48. PubMed ID: 19883737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
    André VM; Cepeda C; Venegas A; Gomez Y; Levine MS
    J Neurophysiol; 2006 Apr; 95(4):2108-19. PubMed ID: 16381805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bicarbonate-Independent Sodium Conductance of Na/HCO
    Choi I; Yang H; Kim E; Lee S
    Curr Issues Mol Biol; 2022 Mar; 44(3):1284-1293. PubMed ID: 35723309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors.
    Masuko T; Namiki R; Nemoto Y; Miyake M; Kizawa Y; Suzuki T; Kashiwagi K; Igarashi K; Kusama T
    J Pharmacol Exp Ther; 2009 Nov; 331(2):522-30. PubMed ID: 19644042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Memantine does not show intracellular block of the NMDA receptor channel.
    Parsons CG; Gilling KE; Jatzke C
    Eur J Pharmacol; 2008 Jun; 587(1-3):99-103. PubMed ID: 18456253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
    Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM
    Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An integrated approach to evaluate the functional effects of disease-associated NMDA receptor variants.
    Moody G; Musco A; Bennett J; Wollmuth LP
    Neuropharmacology; 2023 Dec; 240():109703. PubMed ID: 37689262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors.
    Song R; Zhang J; Perszyk RE; Camp CR; Tang W; Kannan V; Li J; Xu Y; Chen J; Li Y; Liang SH; Traynelis SF; Yuan H
    J Neurochem; 2023 Aug; ():. PubMed ID: 37649269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Missense variants in RPH3A cause defects in excitatory synaptic function and are associated with a clinically variable neurodevelopmental disorder.
    Pavinato L; Stanic J; Barzasi M; Gurgone A; Chiantia G; Cipriani V; Eberini I; Palazzolo L; Di Luca M; Costa A; Marcantoni A; Biamino E; Spada M; Hiatt SM; Kelley WV; Vestito L; Sisodiya SM; ; Efthymiou S; Chand P; Kaiyrzhanov R; Bruselles A; Cardaropoli S; Tartaglia M; De Rubeis S; Buxbaum JD; Smedley D; Ferrero GB; Giustetto M; Gardoni F; Brusco A
    Genet Med; 2023 Nov; 25(11):100922. PubMed ID: 37403762
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Gheța I; Teleanu RI; Roza E; Carapancea E; Vladacenco O; Teleanu DM
    Neurol Int; 2021 Apr; 13(2):184-189. PubMed ID: 33946630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A
    Zhang J; Tang W; Bhatia NK; Xu Y; Paudyal N; Liu D; Kim S; Song R; XiangWei W; Shaulsky G; Myers SJ; Dobyns W; Jayaraman V; Traynelis SF; Yuan H; Bozarth X
    Front Genet; 2021; 12():694312. PubMed ID: 34413877
    [No Abstract]   [Full Text] [Related]  

  • 54. Identification of a Novel Mutation in
    Sarigecili E; Direk MC; Komur M; Bozdogan ST; Okuyaz C
    Ann Indian Acad Neurol; 2020; 23(5):696-699. PubMed ID: 33623275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Author Correction: Voltage-independent GluN2A-type NMDA receptor Ca
    Bertocchi I; Eltokhi A; Rozov A; Chi VN; Jensen V; Bus T; Pawlak V; Serafino M; Sonntag H; Yang B; Burnashev N; Li SB; Obenhaus HA; Both M; Niewoehner B; Single FN; Briese M; Boerner T; Gass P; Rawlins JNP; Köhr G; Bannerman DM; Sprengel R
    Commun Biol; 2021 Feb; 4(1):187. PubMed ID: 33564096
    [No Abstract]   [Full Text] [Related]  

  • 56. Response to immunotherapy in a patient with Landau-Kleffner syndrome and GRIN2A mutation.
    Fainberg N; Harper A; Tchapyjnikov D; Mikati MA
    Epileptic Disord; 2016 Mar; 18(1):97-100. PubMed ID: 26806548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.
    Afshari P; Myles-Worsley M; Cohen OS; Tiobech J; Faraone SV; Byerley W; Middleton FA
    Mol Neuropsychiatry; 2015 Oct; 1(3):125-44. PubMed ID: 26380821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia.
    Gao K; Tankovic A; Zhang Y; Kusumoto H; Zhang J; Chen W; XiangWei W; Shaulsky GH; Hu C; Traynelis SF; Yuan H; Jiang Y
    PLoS One; 2017; 12(2):e0170818. PubMed ID: 28182669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers.
    Li D; Yuan H; Ortiz-Gonzalez XR; Marsh ED; Tian L; McCormick EM; Kosobucki GJ; Chen W; Schulien AJ; Chiavacci R; Tankovic A; Naase C; Brueckner F; von Stülpnagel-Steinbeis C; Hu C; Kusumoto H; Hedrich UB; Elsen G; Hörtnagel K; Aizenman E; Lemke JR; Hakonarson H; Traynelis SF; Falk MJ
    Am J Hum Genet; 2016 Oct; 99(4):802-816. PubMed ID: 27616483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetic contributions to gating by interactions unique to N-methyl-D-aspartate (NMDA) receptors.
    Borschel WF; Cummings KA; Tindell LK; Popescu GK
    J Biol Chem; 2015 Oct; 290(44):26846-55. PubMed ID: 26370091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.